Management of Antineutrophil Cytoplasmic Antibody-Associated Alveolar Hemorrhage: A Bayesian Reanalysis of the PEXIVAS Trial.
J RheumatolOct 1, 2026 (epub)
Omri A Arbiv, Lee Fidler, Sindhu R Johnson et al.
✦ AI-curated · Sources linked
In 30 seconds
This Bayesian reanalysis of the PEXIVAS trial focused on adults with antineutrophil cytoplasmic antibody-associated vasculitis and diffuse alveolar hemorrhage (DAH). It found a 93% probability of improved survival with plasma exchange (PLEX) for DAH patients (HR 0.52) and a 98% probability of improved survival with reduced-dose glucocorticoids for those without DAH (HR 0.46).
Key findings
- 93% probability of improved survival with PLEX for patients with DAH (HR 0.52).
- 67% probability of improved survival without DAH (HR 0.86).
- 98% probability of improved survival with reduced-dose glucocorticoids without DAH (HR 0.46).
- Plasma exchange increased the odds of severe infection (OR 1.25).
Why it matters
Understanding the effects of plasma exchange and glucocorticoid dosing in patients with antineutrophil cytoplasmic antibody-associated vasculitis and diffuse alveolar hemorrhage is crucial for optimizing treatment strategies and improving patient outcomes.